Rodin Therapeutics, Inc.

Alkermes plc is preparing to launch its first novel product, the antipsychotic ALKS-3831, after focusing for many years on drug delivery. ALKS-3831 could launch shortly; it’s pending at the US Food a

Funding for start-ups and other early-stage companies continues to flow into the biopharmaceutical industry from new and established sources. That includes Novo Holdings’ REPAIR Impact Fund, which has

Alkermes PLC entered 2020 with a sharper research and development focus that may lead to the first novel drugs for a company that’s known for improving established molecules. CEO Richard Pops explain

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Vertex Partners With Molecul